Welcome to the Hope Bio Blog

Inspired by results in other autoimmune conditions By Jan Shultis Billions of stem cells manufactured through proprietary technology by Houston-area biotechnology company Hope Biosciences have the regulatory “green light” to join the fight against Crohn’s Disease. The U.S. Food and Drug Administration (FDA) has authorized a Phase II clinical trial to evaluate whether the stem cells manufactured through Hope’s proprietary technology affect signs and symptoms of Crohn’s Disea

Written by Jan Shultis Billions of stem cells manufactured through proprietary technology by Houston-area biotechnology company Hope Biosciences are soon to be pressed into the fight against Alzheimer’s Disease (AD). The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, an

Written by Jan Shultis Sugar Land, Texas, 1 NOV 2024: Hope Biosciences, a clinical-stage biotechnology company that manufactures mesenchymal stem cell therapeutics through proprietary technology unprecedented in its ability to create repeatable treatments, today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing remitting m